

Liz Lightstone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4599346/publications.pdf>

Version: 2024-02-01

117
papers

6,353
citations

76326

40
h-index

71685

76
g-index

124
all docs

124
docs citations

124
times ranked

8268
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune gene expression and functional networks in distinct lupus nephritis classes. <i>Lupus Science and Medicine</i> , 2022, 9, e000615.	2.7	3
2	BLISS-LN trial revisited: function matters. <i>Kidney International</i> , 2022, 101, 224-226.	5.2	0
3	Comparison of catheters or new arteriovenous fistulas for commencement of haemodialysis in pregnant women with chronic kidney disease: an international observational study. <i>Journal of Nephrology</i> , 2022, 35, 1689-1698.	2.0	2
4	A Core Outcome Set for Trials in Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 53-64.	4.5	4
5	COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry. <i>Kidney360</i> , 2022, 3, 293-306.	2.1	10
6	Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients. <i>Kidney International Reports</i> , 2022, 7, 1406-1409.	0.8	26
7	The impact of chronic kidney disease Stages 3â€“5 on pregnancy outcomes. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2008-2017.	0.7	43
8	Informing the Risk of Kidney Transplantation Versus Remaining on the Waitlist in the Coronavirus Disease 2019 Era. <i>Kidney International Reports</i> , 2021, 6, 46-55.	0.8	28
9	Anti-Mâ¼llerian hormone concentrations in women with chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 537-542.	2.9	7
10	Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring. <i>Kidney International</i> , 2021, 99, 227-237.	5.2	33
11	SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19. <i>Kidney Medicine</i> , 2021, 3, 54-59.e1.	2.0	5
12	Type I interferons affect the metabolic fitness of CD8+ T cells from patients with systemic lupus erythematosus. <i>Nature Communications</i> , 2021, 12, 1980.	12.8	56
13	Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. <i>Lancet, The</i> , 2021, 397, 1178-1181.	13.7	279
14	Answering the call to action: rapid implementation of an in-center hemodialysis SARS-CoV-2 vaccination program. <i>Kidney International</i> , 2021, 99, 1238-1239.	5.2	6
15	Serologic Screening for Coronavirus Disease 2019 in Patients With Glomerular Disease. <i>Kidney International Reports</i> , 2021, 6, 1402-1406.	0.8	3
16	MO126CLINICAL AND BIOMARKER CHARACTERISTICS OF PATIENTS WITH C3G OR IC-MPGN ENROLLED IN TWO PHASE II STUDIES INVESTIGATING THE FACTOR D INHIBITOR DANICOPAN*. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	2
17	Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. <i>Kidney International</i> , 2021, 99, 1470-1477.	5.2	58
18	Placental and endothelial biomarkers for the prediction of superimposed pre-eclampsia in chronic kidney disease. <i>Pregnancy Hypertension</i> , 2021, 24, 58-64.	1.4	12

#	ARTICLE	IF	CITATIONS
19	Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1322-1329.	0.9	188
20	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. <i>Kidney International</i> , 2021, 100, 881-893.	5.2	7
21	Identification of Patient Characteristics Associated With SARS-CoV-2 Infection and Outcome in Kidney Transplant Patients Using Serological Screening. <i>Transplantation</i> , 2021, 105, 151-157.	1.0	17
22	Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients. <i>Lancet, The</i> , 2021, 398, 1482-1484.	13.7	58
23	Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus. <i>Annals of Internal Medicine</i> , 2021, 174, 1647-1657.	3.9	64
24	A focus group study of self-management in patients with glomerular disease.. <i>Kidney International Reports</i> , 2021, 7, 56-67.	0.8	2
25	High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1969-1975.	6.1	128
26	Glomerular Disease and Pregnancy. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 469-476.	1.4	6
27	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 673-684.	4.5	66
28	Patient and Caregiver Perspectives on Terms Used to Describe Kidney Health. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 937-948.	4.5	47
29	Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 209-218.	4.5	38
30	Updates in Diagnosis and Management of Preeclampsia in Women with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1371-1380.	4.5	32
31	Patient and Caregiver Priorities for Outcomes in CKD: A Multinational Nominal Group Technique Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 679-689.	1.9	56
32	Clinical practice guideline on pregnancy and renal disease. <i>BMC Nephrology</i> , 2019, 20, 401.	1.8	124
33	Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial. <i>BMC Nephrology</i> , 2019, 20, 352.	1.8	6
34	Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis. <i>Kidney International</i> , 2019, 95, 655-665.	5.2	33
35	Standardized Outcomes in Nephrologyâ€”Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. <i>Kidney International</i> , 2019, 95, 1280-1283.	5.2	20
36	Diagnostic Indicators of Superimposed Preeclampsia in Women With CKD. <i>Kidney International Reports</i> , 2019, 4, 842-853.	0.8	23

#	ARTICLE	IF	CITATIONS
37	Serum Creatinine in Pregnancy: A Systematic Review. <i>Kidney International Reports</i> , 2019, 4, 408-419.	0.8	70
38	Hydroxychloroquine blood concentration in lupus nephritis: a determinant of disease outcome?. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1604-1610.	0.7	32
39	Glomerular Disease in Women. <i>Kidney International Reports</i> , 2018, 3, 258-270.	0.8	12
40	Kidneys and women's health: key challenges and considerations. <i>Nature Reviews Nephrology</i> , 2018, 14, 203-210.	9.6	15
41	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. <i>Rheumatology</i> , 2018, 57, 14-18.	1.9	43
42	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , 2018, 57, e1-e45.	1.9	247
43	Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. <i>Rheumatology</i> , 2018, 57, 1156-1161.	1.9	58
44	Can we manage lupus nephritis without chronic corticosteroids administration?. <i>Autoimmunity Reviews</i> , 2018, 17, 4-10.	5.8	37
45	Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate. <i>Autoimmunity Reviews</i> , 2018, 17, 11-18.	5.8	19
46	FP187TWENTY YEARS OF LUPUS NEPHRITIS MANAGEMENT - EVALUATION OF A MULTI ETHNIC PATIENT COHORT TO IDENTIFY FACTORS AFFECTING OUTCOME. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i92-i92.	0.7	1
47	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. <i>Rheumatology</i> , 2018, 57, 1502-1503.	1.9	12
48	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 543-546.	0.9	154
49	Pregnancy in chronic kidney disease and kidney transplantation. <i>Kidney International</i> , 2017, 91, 1047-1056.	5.2	96
50	Altered expression of signalling lymphocyte activation molecule receptors in T-cells from lupus nephritis patients—a potential biomarker of disease activity. <i>Rheumatology</i> , 2017, 56, 1206-1216.	1.9	12
51	Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i123-i128.	0.7	33
52	A Multicenter Cohort Study of Histologic Findings and Long-Term Outcomes of Kidney Disease in Women Who Have Been Pregnant. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 408-416.	4.5	19
53	Manifestations of lupus in the kidney and how to manage them. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1614-1616.	0.7	1
54	Lupus Nephritis and Pregnancy: Concerns and Management. <i>Seminars in Nephrology</i> , 2017, 37, 347-353.	1.6	39

#	ARTICLE	IF	CITATIONS
55	Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features—A renal biopsy. <i>Kidney International</i> , 2017, 92, 1223-1231.	5.2	55
56	A complicated multisystem flare of systemic lupus erythematosus during pregnancy. <i>BMJ Case Reports</i> , 2017, 2017, bcr2016217546.	0.5	2
57	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap. <i>Kidney International Reports</i> , 2016, 1, 327-339.	0.8	1
58	Diagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease. <i>Kidney International</i> , 2016, 89, 874-885.	5.2	124
59	Lupus nephritis management guidelines compared. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 904-913.	0.7	97
60	The exaggerated inflammatory response in Behçet's syndrome: identification of dysfunctional post-transcriptional regulation of the IFN- β /CXCL10 IP-10 pathway. <i>Clinical and Experimental Immunology</i> , 2015, 181, 427-433.	2.6	17
61	Eculizumab as rescue therapy in severe resistant lupus nephritis: Fig. 1. <i>Rheumatology</i> , 2015, 54, kev307.	1.9	40
62	Kidney disease and pregnancy. <i>Medicine</i> , 2015, 43, 550-555.	0.4	4
63	Rituximab in Systemic Lupus Erythematosus and Lupus Nephritis. <i>Nephron Clinical Practice</i> , 2015, 128, 250-254.	2.3	37
64	Necrotizing and crescentic glomerulonephritis presenting with preserved renal function in patients with underlying multisystem autoimmune disease: a retrospective case series. <i>Rheumatology</i> , 2015, 54, 1025-1032.	1.9	12
65	Tacrolimus is an effective treatment for lupus nephritis in pregnancy. <i>Lupus</i> , 2014, 23, 1192-1196.	1.6	68
66	Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1280-1286.	0.9	382
67	Minimising steroids in lupus nephritis—will B cell depletion pave the way?. <i>Lupus</i> , 2013, 22, 390-399.	1.6	25
68	Severe pre-eclampsia and hypertensive crises. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2013, 27, 877-884.	2.8	69
69	Breastfeeding and Tacrolimus. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 563-567.	4.5	114
70	Renoprotective strategies in lupus nephritis: beyond immunosuppression. <i>Lupus</i> , 2013, 22, 1267-1273.	1.6	21
71	Seasonal Relapsing Minimal Change Disease: A Novel Strategy for Avoiding Long-Term Immunosuppression. <i>Case Reports in Nephrology and Urology</i> , 2012, 2, 102-107.	1.5	0
72	A multi-centre qualitative study exploring the experiences of UK South Asian and White Diabetic Patients referred for renal care. <i>BMC Nephrology</i> , 2012, 13, 157.	1.8	5

#	ARTICLE	IF	CITATIONS
73	Joint European League Against Rheumatism and European Renal Associationâ€œEuropean Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.9	868
74	The landscape after LUNAR: Rituximab's craterâ€œfilled path. <i>Arthritis and Rheumatism</i> , 2012, 64, 962-965.	6.7	34
75	Pre-pregnancy counseling for women with chronic kidney disease. <i>Journal of Nephrology</i> , 2012, 25, 450-459.	2.0	44
76	LACK OF AWARENESS OF KIDNEY COMPLICATIONS DESPITE FAMILIARITY WITH DIABETES: A MULTIâ€œETHNIC QUALITATIVE STUDY. <i>Journal of Renal Care</i> , 2011, 37, 2-11.	1.2	16
77	Renal disease and pregnancy. <i>Medicine</i> , 2011, 39, 497-501.	0.4	2
78	Lupus nephritis: where are we now?. <i>Current Opinion in Rheumatology</i> , 2010, 22, 252-256.	4.3	34
79	Genetic loci influencing kidney function and chronic kidney disease. <i>Nature Genetics</i> , 2010, 42, 373-375.	21.4	246
80	Pregnancy in pancreasâ€œkidney transplant recipients: report of three cases and review of the literature. <i>Obstetric Medicine</i> , 2010, 3, 73-77.	1.1	16
81	Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3717-3723.	0.7	141
82	European consensus statement on the terminology used in the management of lupus glomerulonephritis. <i>Lupus</i> , 2009, 18, 257-263.	1.6	131
83	Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2009, 9, 82-89.	5.8	62
84	Natural regulatory T cells: number and function are normal in the majority of patients with lupus nephritis. <i>Clinical and Experimental Immunology</i> , 2008, 153, 44-55.	2.6	60
85	Chapter 16 Systemic Lupus Erythematosus: Renal Involvement. <i>Handbook of Systemic Autoimmune Diseases</i> , 2007, , 311-321.	0.1	0
86	A patient with suspected miscarriage is found to have hypertension, renal failure, and thrombocytopenia: case outcome. <i>BMJ: British Medical Journal</i> , 2007, 335, 205-206.	2.3	1
87	A patient with suspected miscarriage is found to have hypertension, renal failure, and thrombocytopenia: case presentation. <i>BMJ: British Medical Journal</i> , 2007, 334, 1372-1372.	2.3	0
88	A patient with suspected miscarriage is found to have hypertension, renal failure, and thrombocytopenia: case progression. <i>BMJ: British Medical Journal</i> , 2007, 335, 44-44.	2.3	0
89	Renal disease and pregnancy. <i>Medicine</i> , 2007, 35, 524-528.	0.4	1
90	Distal renal tubular acidosis in association with HIV infection and AIDS. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1420-1422.	0.7	9

#	ARTICLE	IF	CITATIONS
91	Urinary proteomic profiles distinguish between active and inactive lupus nephritis. <i>Rheumatology</i> , 2006, 45, 1497-1504.	1.9	90
92	Haplotype structure of TNFRSF5-TNFSF5 (CD40â€“CD40L) and association analysis in systemic lupus erythematosus. <i>European Journal of Human Genetics</i> , 2005, 13, 669-676.	2.8	23
93	Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. <i>Kidney International</i> , 2003, 64, 1685-1694.	5.2	102
94	Preventing renal disease: The ethnic challenge in the United Kingdom. <i>Kidney International</i> , 2003, 63, S135-S138.	5.2	15
95	END-STAGE RENAL FAILURE IN INDO-ASIANS IN THE UK: A DOUBLE WHAMMY. <i>Transplantation</i> , 2002, 73, 1533-1534.	1.0	2
96	High Rates of Tuberculosis in End-Stage Renal Failure: the Impact of International Migration. <i>Emerging Infectious Diseases</i> , 2002, 8, 77-78.	4.3	51
97	Goodpasture's disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. <i>American Journal of Kidney Diseases</i> , 2002, 39, 1162-1167.	1.9	143
98	Goodpasture's disease. <i>Lancet</i> , The, 2001, 358, 917-920.	13.7	155
99	Acute renal failure. <i>Clinical Medicine</i> , 2001, 1, 266-273.	1.9	5
100	Life-threatening thrombosis 18 years after first presentation of primary antiphospholipid antibody syndrome. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 843-845.	0.7	8
101	In Goodpasture's Disease, CD4+ T Cells Escape Thymic Deletion and Are Reactive with the Autoantigen Î±3(IV)NC1. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1908-1915.	6.1	72
102	Lesson of the week: Cholesterol emboli syndrome. <i>BMJ: British Medical Journal</i> , 2000, 321, 1065-1067.	2.3	27
103	Quinine-induced immune thrombocytopenic purpura followed by hemolytic uremic syndrome. <i>American Journal of Kidney Diseases</i> , 1999, 33, 133-137.	1.9	70
104	In the absence of the invariant chain, HLA-DR molecules display a distinct array of peptides which is influenced by the presence or absence of HLA-DM. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 5772-5777.	7.1	46
105	The Endogenous Pathway of MHC Class II Antigen Presentation. <i>Immunological Reviews</i> , 1996, 151, 51-79.	6.0	85
106	Antigen presentation by T cells inhibits IL-2 production and induces IL-4 release due to altered cognate signals. <i>Journal of Immunology</i> , 1996, 156, 2769-75.	0.8	32
107	High incidence of end-stage renal disease in Indo-Asians in the UK. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1995, , .	0.5	16
108	Expression in vivo of CD45RA, CD45RB and CD44 on T cell receptor-transgenic CD8+ T cells following immunization. <i>European Journal of Immunology</i> , 1995, 25, 1755-1759.	2.9	20

#	ARTICLE	IF	CITATIONS
109	Hyper-reactivity of mouse CD45RA ⁺ T cells. European Journal of Immunology, 1993, 23, 2383-2386.	2.9	11
110	CD45RA ⁺ T Cells: Not Simple Virgins. Clinical Science, 1993, 85, 515-519.	4.3	14
111	Memory in helper T cells of minor histocompatibility antigens, revealed in vivo by alloimmunizations in combination with Thy-1 antigen. European Journal of Immunology, 1992, 22, 115-122.	2.9	19
112	In the mouse the maturation stage of the peripheral CD4 ⁺ CD45RA ⁺ subset is different from that of the CD8 ⁺ CD45RA ⁺ subset. European Journal of Immunology, 1991, 21, 2161-2165.	2.9	11
113	Antigen presentation by dendritic cells provides optimal stimulation for the production of interleukin (IL) 2, IL 4 and interferon- γ by allogeneic T cells. European Journal of Immunology, 1991, 21, 2803-2809.	2.9	27
114	Anti-cd45ra antibodies increase the proliferation of mouse t cells to phytohemagglutinin through the interleukin 2/interleukin 2 receptor pathway. European Journal of Immunology, 1989, 19, 2005-2010.	2.9	22
115	Prepregnancy counselling and risk assessment: general overview. , 0, , 21-30.		2
116	Postpartum follow-up of antenatally identified renal problems. , 0, , 53-58.		0
117	Lupus and Vasculitis in Pregnancy. , 0, , 157-169.		0